A federal judge denied plaintiffs’ motion to gather drug companies’ analysis of pancreatic cancer cases among users of their type 2 diabetes drugs; however, his decision is still pending regarding plaintiffs’ request to gather adverse event reports involving those drugs submitted to the U.S. Food and Drug Administration (FDA). U.S. District Judge Anthony Battaglia is presiding over a multidistrict litigation (MDL) involving about 460 plaintiffs who allege they developed pancreatic cancer after taking one of four drugs in a class of type 2 diabetes drugs known as incretin mimetics. The lawsuits name Amylin Pharmaceuticals and Eli Lilly & Co., for the drug Byetta; Merck ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.